Familial hypercholesterolemia (FH) is an inherited disorder of lipid metabolism characterized by premature cardiovascular disease. It is one of the most common metabolic disorders affecting humans. There are two clinical manifestations: the milder heterozygous form and more severe homozygous form. Despite posing a significant health risk, FH is inadequately diagnosed and managed. As the clinical outcome is related to the degree and duration of exposure to elevated low-density lipoprotein cholesterol (LDL-C) levels, early treatment is vital. Diagnosis can usually be made using a combination of clinical characteristics such as family history, lipid levels, and genetic testing. Mutations in the gene encoding the LDL receptor (LDLR), apolipoprotein B, the pro-protein convertase subtilisin/kexin 9 (PCSK9), and LDLR adaptor protein are the commonest abnormalities. Early
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INTRODUCTION
Familial hypercholesterolemia (FH) is an inherited autosomal dominant disorder of premature atherosclerosis [1] . It was first described in the late 1930s by Carl Mt‹ ller, a Norwegian clinician in a landmark paper by putting forward the idea that hypercholesterolemia and tendinous xanthomas were linked to cardiovascular (CV) disease through a single gene inheritance [2] .
The clinical phenotype was further characterized in 1964 into the mild heterozygous (HeFH) and more severe homozygous (HoFH) forms with dominant inheritance [3] . While Dr Mt‹ ller had initially postulated that causal and prophylactic intervention may be beneficial, it was almost 50 years before this became a possibility.
Historically, untreated HeFH begins to manifest its clinical consequences in the fourth decade in men and fifth decade in women. Patients with HoFH, however, may suffer significant CV events as early as in the first decade of life. By early adulthood, these patients without treatment have 100 times greater mortality risk from CV disease resulting from coronary atherosclerosis or supra-vascular aortic valve calcification as compared to those without FH [1] . In general, those with HoFH do not survive past 30 years without therapeutic interventions [1] . Ever since the work of Goldstein and Brown in 1983, it had been generally accepted that FH has a population prevalence of 1:500 in HeFH and 1:1,000,000 in HoFH [4] . These figures, however, vastly underestimate the true prevalence. Recent work by the European Atherosclerosis Society (EAS) noted widening inconsistency of diagnosis, with 71 % of patients with FH diagnosed in Netherlands, 43 % in Norway, and only 6 % in Spain [5] . In addition, these figures were only obtainable for 22 countries out of approximately 200 in the world. Despite posing a significant health and economic burden, the true prevalence is yet to be accurately determined. Data suggest that HoFH may actually affect 1 in 160,000-300,000 people [6] . The Copenhagen General Population Study and EAS estimate an HeFH prevalence of 1:200 instead of the historical 1:500, which would mean that between 14 and 34 million individuals may in fact be affected worldwide [5] . This represents a staggering number whose risk may be easily reduced with lipid-lowering therapy, yet are currently being overlooked.
In this article, we review the disease of FH, complexity of diagnosis and management, and the challenges faced in preventing the significant morbidity and mortality associated with it. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
PATHOPHYSIOLOGY
Abnormal elevations in plasma low-density lipoprotein cholesterol (LDL-C) in FH are largely due to functional genetic mutations in the LDL receptor (LDLR), and less frequently apolipoprotein B (ApoB) or gain-of-function mutations of pro-protein convertase subtilisin/ kexin 9 (PCSK9). Autosomal recessive FH is associated with LDLR-adaptor protein (LDLRAP) mutation [1] . These mutations mainly result in four molecular defects: failed internalization of bound LDL, reduced LDL binding, lack of receptor expression, and failure of LDLR to reach the plasma membrane [7] . Hepatocyte and peripheral cell-regulated endocytosis of LDL-C occurs via ApoB, a protein that transports lipids through the lymphatic and circulatory system. Genetic mutation of ApoB leads to decreased LDL affinity for the LDLR and reduced hepatic LDL plasma clearance. FH is also associated with raised levels of lipoprotein (a) [Lp(a)] by an unknown mechanism [8] . Lp(a) levels are higher in HoFH than HeFH.
Defective high-density lipoprotein (HDL)driven cholesterol efflux may also be associated with low levels of HDL cholesterol in HoFH [8] . If FH is inadequately treated or untreated, it leads to cholesterol retention in the arterial wall with foam cell formation within the intima, accelerated occlusive atherosclerosis, and early CV disease [5, 9] .
HeFH is characterized by only one normal allele and may be due to loss-of-function LDLR mutation, gain-of-function mutation in PCSK9, or mutations in ApoB affecting the LDLRbinding domain [5] . To date, more than 1200 LDLR mutations are documented in this gene [9] . HoFH, on the other hand, is relatively rare with patients having two mutant copies of the gene, with impaired LDLR function being the most common and associated with devastating clinical consequences. Other variations of the clinical HoFH phenotype include compound heterozygotes with mutations at two different sites of the same gene or double heterozygotes, for example having one copy of ApoB gene defect and one copy of an LDL-R defect.
CLINICAL PRESENTATION AND DIAGNOSIS
In the primary care setting, the diagnosis of FH may be easily missed. Patients are commonly only identified after experiencing a CV event at an unexpected age or as a result of a family member being diagnosed. HoFH is likely when LDL-C levels are greater than 13 mmol/L (500 mg/dL) in adults and 11 mmol/L (420 mg/dL) in children [10] . Triglyceride (TG) levels may remain normal [11] . LDLR-negative HoFH patients usually have a worse prognosis, succumbing to complications by the second decade [6] . In addition to cholesterol levels, diagnosis may be supported by features seen during physical examination such as tendon xanthomas on the dorsal aspect of the metacarpophalangeal joints or at the calcaneal tendon, and arcus senilis. The EAS diagnostic criterion for HoFH is outlined in Table 1 [12] .
For early effective prevention of CV disease, HeFH should be suspected in asymptomatic individuals with elevated plasma total cholesterol (TC) or LDL-C concentrations, relevant clinical history, physical signs, or a family history of premature coronary disease.
TC levels greater than 6.7 mmol/L (260 mg/dL) and 7.5 mmol/L (290 mg/dL)-or untreated LDL-C levels greater than 4 mmol/L (155 mg/ dL) and 4.9 mmol/L (190 mg/dL)-warrant further investigation in children and adults, respectively, after exclusion of secondary causes of hypercholesterolemia such as diabetes, hypothyroidism, and obesity [5, 13] .
Although clinical and biochemical findings provide valuable diagnostic information, specialized genetic testing is often required. With the advent of DNA-based mutation screening methods, direct detection of mutations in the LDLR, ApoB, PCSK9, and LDLRAP genes are now widely utilized.
However, it is reported that up to 40 % of patients with a clinical diagnosis may in fact not have a genetic diagnosis of their hyperlipidemia [14, 15] . This may be due to causal mutations yet to be discovered, Early Death (MEDPED) [17] [18] [19] . The Simon Broome and the Dutch criteria take into account the family history, clinical history, physical signs, LDL-C concentration, and molecular genetic testing results to classify the likelihood of FH. The main difference between the two being that the Simon Broome criteria recognizes DNA evidence of a mutation as evidence of definite FH, while the Dutch require one other criteria to be met in addition to the molecular diagnosis for definite FH. All three systems also use different age cutoffs for defining premature coronary heart disease (CHD). The US MEDPED criterion uses age-specific thresholds of TC concentration to diagnose FH with TC cutoff levels being lower in the first-, second-and third-degree relatives than the general population. The main disadvantages of its use are that clinical characteristics and FH-associated gene mutation are not considered. Risk factors such as hypertension, diabetes, and smoking should be addressed. Although these measures are of benefit, they are unlikely to lower the LDL-C levels sufficiently and direct intervention is invariably needed to reduce the levels. Table 1 The diagnostic criteria of homozygous familial hypercholesterolemia (adapted from the European Atherosclerosis Society guidelines) [5] (a) Two mutant alleles at the LDLR, ApoB, PCSK9, or LDLRAP1 gene locus 
TREATMENT

Treatment for HeFH
To date, no randomized controlled trials have been conducted assessing the benefit of lipidmodification treatment on CHD events among patients with HeFH. As such, much of the pharmacotherapy currently used is based on an extrapolation of data among non-FH patients or from a few observational studies conducted principally using hydroxymethylglutaryl coenyzme A (HMG CoA) reductase inhibitors (statins) in patients with FH [20, 21] . Statins remain the only class of lipid-lowering therapy to reduce total and coronary mortality postmyocardial infarction. It is widely accepted that maximal potent statin dose should be initiated as first-line therapy in adults post-diagnosis of HeFH [5] . If started prophylactically in early adulthood, statin use has been shown to lower the risk of CHD by up to 80 % [20] . NICE recommends a target of 50 % reduction in LDL-C concentration [22] . In accordance with the European Society of Cardiology, the EAS has outlined new LDL targets [5] :
• children\3.5 mmol/L (\135 mg/dL); • adults\2.5 mmol/L (\100 mg/dL);
• adults with CHD or diabetes\1.8 mmol/L (\70 mg/dL).
Although the 2013 American College of Cardiology/American Heart Association
Guidelines do not recommend a target LDL level, high-intensity statin therapy is recommended in asymptomatic arteriosclerotic CV disease (ASCVD) with LDL-C levels greater than 190 mg/dL where tolerated [23] . Due to its net benefit in terms of reduction in ASCVD risk versus potential adverse effects, statin therapy is recommended for those at increased risk.
Despite maximal dose statin therapy, LDL-C levels may yet remain elevated. The addition of ezetimibe (a cholesterol absorption inhibitor) to statins or as monotherapy reduces CVD events with NICE and EAS both recommending its coadministration, which may help reduce LDL-C levels by 60 to 70 % in total [18, 21] [18] . Colesevelam is preferred due to its lower gastrointestinal side effect profile than cholestyramine and colestipol, both of which are also associated with poor patient compliance and significant multi-drug interactions [24] .
Despite a lack of evidence of the clinical benefit of niacin co-administration, high-dose therapy has until recently been recommended, especially in the USA and Canada where its use had doubled [23, 25, 26] . Its availability in Europe has started to decline due to two recently published neutral CVD outcome studies. The AIM-HIGH (ClinicalTrials.gov #NCT00120289) study was prematurely stopped at 3 years due to a lack of clinical benefit of niacin therapy when compared to placebo in patients with established CV disease who were already being treated with statins and ezetimibe [27] . One of the criticisms of the study was that it was not powered to determine a difference in CV events. The recent randomized, placebo-controlled HPS2-THRIVE (ClinicalTrials.gov #NCT00461630) trial attempted to address this by recruiting 25,673 patients with atherosclerotic vascular disease and also found no benefit of the addition of niacin therapy to statin-based LDL-C-lowering therapy on major vascular events [28] . [5, 32, 33] .
Treatment for HoFH
All patients with HoFH should be initiated on lipid-lowering therapy as early as possible, with LDL-C targets the same as in HeFH [6] . Statins remain the cornerstone of treatment with the observed benefit due to inhibition of hepatic lipoprotein synthesis, up-regulation of LDLR, or an increase in trans-intestinal cholesterol excretion [34] . While no randomized controlled trials have been conducted looking at the end point of CV mortality in HoFH, statins in the non-FH population are known to reduce the incidence of major vascular events in primary prevention, with intensive regimens producing greater reduction than less intensive regimens [35, 36] . In HoFH, observational studies show a dose-dependent effect on LDL-C reduction and maximum tolerable doses should generally be prescribed [37, 38] . [12] .
Liver transplantation was first described in 1983 and has now emerged as the most effective treatment, markedly improving LDL-C levels long term [46, 47] . Surgery provides a liver with functional LDLRs, thereby correcting the molecular defect. It is indicated in patients who despite maximal medical therapy and apheresis fail to reduce LDL-C levels sufficiently. Although successful, it poses significant challenges including procedurerelated morbidity and mortality, lack of available donors, and the need for long-term 
Mipomersen
Mipomersen is an antisense oligonucleotide targeting the messenger ribonucleic acid of ApoB with eventual reduction in the secretion of VLDL [6] . It was approved by the FDA in January 2013 based on a randomized, doubleblinded, placebo-controlled study of 51 patients with HoFH [52] . Mipomersen was seen to reduce LDL-C levels by 25 %, ApoB by 27 %, and Lp(a) by 31 % when compared to placebo (stable low-fat diet, pre-existing maximal tolerated lipid-lowering drugs, and those not receiving apheresis). However, doubts remain due to its significant side effects as the EMA rejected its use in March 2013 [53] . EMA noted that a high proportion of patients stopped the drug within 2 years due to liver dysfunction and there were uncertainties of its effect on longterm CV outcome. Numerical imbalance in overall CV events, major adverse cardiac events, and CV-associated hospitalization compared to placebo were of considerable concern [6]. The commonest reason for discontinuation of mipomersen is injection site reactions, such as erythema, pain, pruritus, and local swelling, being seen in around 78 % of patients [54] . Further evaluation of the longterm efficacy, outcome, and side effects is urgently required.
PCSK9 Inhibitors
LDLR is a cell-surface receptor playing a vital role in regulating the circulating cholesterol levels. It allows LDL binding with subsequent endocytosis and lysosomal degradation, following which it is recycled back to the plasma membrane [55] . PCSK9 is a serine protease secreted in the liver and acts by inhibiting this LDLR recycling with consequential reduction in LDL clearance. PCSK9 binds to LDLR resulting in cointernalization and degradation of the receptor within the lysosome. This inverse relationship between plasma PCSK9 levels and LDLR results in reduced LDL-C metabolism and eventual hypercholesterolemia [56] . Gain-of-function mutation in the PCSK9 gene was first discovered in 2003, linking it to a phenotype identical to classical FH [57] . What caused widespread interest was the discovery that lossof-function mutation resulted in low plasma levels of LDL-C and ApoB and thus protection against CHD events [58] . of which at least one was defective [66] . Benefit has also been noted in patients with HeFH. The RUTHERFORD-2 (ClinicalTrials.gov #NCT017 63918) trial randomly assigned 331 patients with HeFH to evolocumab or placebo every 2 or 4 weeks [67] . Being assigned to the monoclonal antibody resulted in 56-63 % reduction in LDL-C after 12 weeks in patients already receiving a statin and 60 % of those who were taking ezetimibe. These trials have shown promising results, especially in patients with high cholesterol who cannot tolerate statins or where other lipid-lowering therapy does not reduce the LDL-C levels enough. The long-term safety of these compounds and very low DL-C remain unclear and data from larger phase 3 or 4 trials are keenly awaited.
Gene Therapy
The primary defect in 85 % of FH cases is mutation or deletion of the LDLR-encoding gene responsible for removing LDL-C via endocytosis and intracellular degradation [11] . The availability of functional LDLRs post-liver transplantation in HoFH has provided backing to the idea that gene replacement may constitute an important strategy for treatment.
In animal models, viral vector-based gene transfer has been seen to result in overexpression of LDLR with long-term stabilization in hypercholesterolemia [68] . A pilot study in 1995 in the USA used recombinant retroviruses in five patients with HoFH with inconsistent results [69] . Since then, stepwise technological advances and refinements have been made. Gene therapy using vectors based on serotype 8 of the adeno-associated virus (AAV8) is one of the other methods under development [70] .
Although it remains at an investigational stage, gene therapy does provide an exciting new avenue for future research, especially for patients with HoFH who are LDL-R defective.
CHALLENGES FACED BY THE CLINICIAN
Despite the significant progress in our understanding, FH remains one of the most poorly diagnosed and managed diseases in the world. Early detection and management is not only cost-effective, but also preserves life. Furthermore, there is a broad spectrum of LDL-C levels in FH which make this difficult [71] . There may also be a lack of understanding of FH among cardiologists in particular and overconfidence in the benefits of statin therapy.
Most patients are either simply discharged on moderate or high-intensity statin, cholesterol levels ignored, or simply left to the patient's own general practitioner to investigate further, who is likely to know less than the cardiologist. 
